The Melanoma Research Program is composed of 24 investigators (17 Full and 7 Associate members) from 10 Departments. The Program has 3 major scientific objectives: 1) Develop new prognostic models for patients with primary melanoma that integrate molecular biomarkers with clinical variables;2) Discover the biologic heterogeneity of melanoma with emphasis on molecular alterations that are associated with disease progression and drug resistance;and 3) Develop and integrate emerging novel immunotherapeutic approaches with chemotherapeutic and biological therapies in the treatment of melanoma. Drs. Nina Bhardwaj and Iman Osman are the Co-Leaders for this Program. Total funding increased from $2,739,004 to $4,841,572 since the last competitive application. Membership has increased from 19 to 24 members. Publications for the period total 156, of which 23.7% are intra-programmatic, 20.5% are inter-programmatic, and 12.2% are both intra- and inter-programmatic collaborations.

Public Health Relevance

The incidence of melanoma and deaths due to melanoma continue to increase, but at present there are no successful methods for treatment of advanced disease. The NYUCI Melanonta Program, proposes research that aims to improve detection and therapies that will potentially reduce the number of deaths from melanoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
New York
United States
Zip Code
Snuderl, Matija; Kannan, Kasthuri; Pfaff, Elke et al. (2018) Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nat Commun 9:2868
Formenti, Silvia C; Lee, Percy; Adams, Sylvia et al. (2018) Focal Irradiation and Systemic TGF? Blockade in Metastatic Breast Cancer. Clin Cancer Res 24:2493-2504
Lee, Chul-Hwan; Yu, Jia-Ray; Kumar, Sunil et al. (2018) Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. Mol Cell 70:422-434.e6
Stafford, James M; Lee, Chul-Hwan; Voigt, Philipp et al. (2018) Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma. Sci Adv 4:eaau5935
Jung, Heekyung; Baek, Myungin; D'Elia, Kristen P et al. (2018) The Ancient Origins of Neural Substrates for Land Walking. Cell 172:667-682.e15
Aiello, Nicole M; Maddipati, Ravikanth; Norgard, Robert J et al. (2018) EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell 45:681-695.e4
Xu, Mo; Pokrovskii, Maria; Ding, Yi et al. (2018) c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature 554:373-377
Herline, Krystal; Prelli, Frances; Mehta, Pankaj et al. (2018) Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimers Res Ther 10:54
Litwinoff, Evelyn M S; Gold, Merav Y; Singh, Karan et al. (2018) Myeloid ATG16L1 does not affect adipose tissue inflammation or body mass in mice fed high fat diet. Obes Res Clin Pract 12:174-186
Snetkova, Valentina; Skok, Jane A (2018) Enhancer talk. Epigenomics 10:483-498

Showing the most recent 10 out of 1170 publications